Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4973
Peer-review started: August 2, 2021
First decision: October 2, 2021
Revised: October 29, 2021
Accepted: August 23, 2022
Article in press: August 23, 2022
Published online: September 14, 2022
Long noncoding RNA (lncRNA) ZNFX1-AS1 (ZFAS1) is a newly discovered lncRNA, but its diagnostic value in gastric cancer is unclear.
We investigated the biological effects of ZFAS1 on the survival, proliferation, and migration of gastric cancer cells.
This study aimed to investigate the potential role of ZFAS1 in gastric cancer and to evaluate the clinical significance of ZFAS1 as a biomarker for gastric cancer screening.
RNA extraction, quantitative realtime polymerase chain reaction, lncRNA silencing and overexpression, MTT assay, transwell migration assay, Colony formation assay, protein extraction, immunosorbent assay, and in vivo tumor formation assay were performed in this study.
ZFAS1 amplification was correlated with poor prognosis in gastric cancer. ZFAS1 knockdown inhibited the viability, migration, and proliferation of gastric cancer cells. ZFAS1 overexpression enhanced the viability, migration, and proliferation of gastric cancer cells. LIN28 and CAPRIN1 were the key downstream mediators of ZFAS1 in gastric cancer cells. ZFAS1 was associated with the tumorigenesis of gastric cancer cells in vivo.
LncRNA ZFAS1 is a potential biomarker for gastric cancer.
ZFAS1 plays an oncogenic role in gastric cancer and can be used as a potential diagnostic biomarker and a new therapeutic target for gastric cancer.